These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 20349415

  • 1. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL.
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [Abstract] [Full Text] [Related]

  • 2. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M, Fukagawa M.
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA, Shepler BM.
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [Abstract] [Full Text] [Related]

  • 5. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL, Swan VJ, Jamal SA.
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [Abstract] [Full Text] [Related]

  • 6. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [Abstract] [Full Text] [Related]

  • 7. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [Abstract] [Full Text] [Related]

  • 8. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

  • 9. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N, Lindholm B, Stenvinkel P.
    Semin Dial; 2008 Apr; 21(5):385-9. PubMed ID: 18573137
    [Abstract] [Full Text] [Related]

  • 10. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.
    Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A.
    Am J Kidney Dis; 2011 Mar; 57(3):422-31. PubMed ID: 21239096
    [Abstract] [Full Text] [Related]

  • 11. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA, Savica V, Piccoli A, Fusaro M, D'Angelo A, Davis PA.
    Ren Fail; 2011 Mar; 33(1):11-4. PubMed ID: 21219199
    [Abstract] [Full Text] [Related]

  • 12. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM.
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [Abstract] [Full Text] [Related]

  • 13. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.
    St Peter WL, Liu J, Weinhandl E, Fan Q.
    Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060
    [Abstract] [Full Text] [Related]

  • 14. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A.
    Cardiovasc Pathol; 2012 Mar; 21(5):372-81. PubMed ID: 22425627
    [Abstract] [Full Text] [Related]

  • 15. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K.
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [Abstract] [Full Text] [Related]

  • 16. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN, Dialysis Clinical Outcomes Revisited Investigators.
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [Abstract] [Full Text] [Related]

  • 17. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F.
    G Ital Nefrol; 2010 Jan; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [Abstract] [Full Text] [Related]

  • 18. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM.
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [Abstract] [Full Text] [Related]

  • 19. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 20. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R, Dryja P, Łacina D, Króliczak V, Chrul S, Kacprzyk F.
    Wiad Lek; 2011 May; 64(1):9-14. PubMed ID: 21812357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.